See you!

 👉 Thrilling times ahead for new ATMP submissions - ATMPs with application for marketing authorization from January 12, 2025 onwards will be subject to EU HTA.

🔚 After 8 months of insights, we close our series, as the latest ATMP authorized in the EU was introduced this week. We hope you enjoyed our series.

🔜 However, further insights are expected in the future. The following ATMPs are currently under evaluation and might eventually undergo German HTA (AMNOG):

🔹 Beremagene geperpavec for treatment of wounds in patients with dystrophic epidermolysis bullosa

🔹 Autologous cartilage-derived articular chondrocytes for repair of cartilage defects of the knee joint

🔹 Mozafancogene autotemcel for treatment of Fanconi anemia

🔹 Obecabtagene autoleucel for treatment of B-cell acute lymphoblastic leukemia

🔹 Delandistrogene moxeparvovec for treatment of Duchenne muscular dystrophy

🔹 Dorocubicel for patients requiring stem cell transplantation

🔹 Lifileucel for treatment of melanoma

 

🆕 Applying our view on Market Access, we will keep you informed about developments and insights on ATMPs, especially those, which will be subject to EU HTA. We are happy to share our thoughts on implications.

At the end of the series, we thank Florentin Köhnemann for creating such informative and straight to the point content 👏

 

🔊 Stay tuned for future posts and series.